Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (1890)
All Articles published online
|
Oct 14, 2007 (publication date) through Nov 5, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Gupte G, Mahadevan S, Clarke J, Alton H, Beath S. Sirolimus-related pulmonary toxicity mimicking 'asthma like' symptoms. World J Gastroenterol 2007; 13(38): 5151-5153 [PMID: 17876884 DOI: 10.3748/wjg.v13.i38.5151] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i38/5151.htm |
| Number | Citing Articles |
| 1 |
Johannes E. Wolff, Robert E. Brown, Jamie Buryanek, Stefan Pfister, Tribhawan S. Vats, Michael E. Rytting. Preliminary experience with personalized and targeted therapy for pediatric brain tumors. Pediatric Blood & Cancer 2012; 59(1): 27 doi: 10.1002/pbc.23402
|
| 2 |
Valerie M. Felton, Landon J. Inge, Brigham C. Willis, Ross M. Bremner, Michael A. Smith. Immunosuppression-induced bronchial epithelial–mesenchymal transition: A potential contributor to obliterative bronchiolitis. The Journal of Thoracic and Cardiovascular Surgery 2011; 141(2): 523 doi: 10.1016/j.jtcvs.2010.10.006
|
| 3 |
Current World Literature. Current Opinion in Pulmonary Medicine 2009; 15(1): 79 doi: 10.1097/MCP.0b013e32831fb1f3
|
| 4 |
George J. Dugbartey, Alp Sener. Recent Advances in Therapeutic Drug Monitoring and Clinical Toxicology. 2022; : 255 doi: 10.1007/978-3-031-12398-6_15
|
| 5 |
Yang Yang, Lei Jiang, Hai-Rong Zhu, Wen-Xin Sun, Jing-Yu Mao, Jing-Wen Miao, Yi-Chen Wang, Su-Mei He, Dong-Dong Wang, Xiao Chen. Remedial Dosing Recommendations for Sirolimus Delayed or Missed Dosages
Caused by Poor Medication Compliance in Pediatric Tuberous Sclerosis
Complex Patients. Current Pharmaceutical Design 2024; 30(11): 877 doi: 10.2174/0113816128299479240213151714
|
| 6 |
Matthew M. Hsieh, M. Beth Link, John F. Tisdale. Sirolimus Associated Pneumonitis after Nonmyeloablative Peripheral Blood Stem Cell Transplant for Sickle Cell Disease. Biology of Blood and Marrow Transplantation 2008; 14(2): 256 doi: 10.1016/j.bbmt.2007.11.001
|
| 7 |
Andrea S. Garrod, Rakesh K. Goyal, Daniel J. Weiner. Sirolimus‐induced interstitial lung disease following pediatric stem cell transplantation. Pediatric Transplantation 2015; 19(3) doi: 10.1111/petr.12438
|
| 8 |
Belde Kasap. Sirolimus in pediatric renal transplantation. Pediatric Transplantation 2011; 15(7): 673 doi: 10.1111/j.1399-3046.2011.01575.x
|
| 9 |
Elizabeth L. Kramer, William D. Hardie, Elizabeth M. Mushaben, Thomas H. Acciani, Patricia A. Pastura, Thomas R. Korfhagen, Gurjit Khurana Hershey, Jeffrey A. Whitsett, Timothy D. Le Cras. Rapamycin decreases airway remodeling and hyperreactivity in a transgenic model of noninflammatory lung disease. Journal of Applied Physiology 2011; 111(6): 1760 doi: 10.1152/japplphysiol.00737.2011
|
| 10 |
Patricia Lopez, Sven Kohler, Seema Dimri. Interstitial Lung Disease Associated with mTOR Inhibitors in Solid Organ Transplant Recipients: Results from a Large Phase III Clinical Trial Program of Everolimus and Review of the Literature. Journal of Transplantation 2014; 2014: 1 doi: 10.1155/2014/305931
|